Pharma models changing as patents expire and product lines get smaller
Anyone watching stock markets recently will have noticed that despite overall gains, the pharmaceutical sector has not been performing. Not surprisingly, it is a combination of drugs coming off patent and a lack of a products in the pipeline that…
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.